12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Company News  |  Deals

Gilead, MicroDose Therapeutx deal

Gilead partnered with MicroDose on MicroDose's respiratory syncytial virus (RSV) candidate MDT-637. MicroDose will be responsible for development of the dry powder inhalation product through Phase IIa...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >